In a press release today, San Diego, California based Crinetics Pharmaceuticals reports positive results from their Phase Two trial of PALTUSOTINE (the former CRN00808). This is a new oral medication to treat acromegaly and neuroendocrine tumors for patients with carcinoid syndrome. Read the press release here.
The data shows that paltusotine maintained IGF-1 levels in patients that were switched to once-daily oral paltusotine from commercially available depot injections octreotide or lanreotide. These results allow Crinetics to move paltusotine into Phase Three for patients with acromegaly in the first half of 2021. In our recent podcast with Crinetics, Dr. Alan Krasner has more details on this drug and offers a great explanation of the differences between Phase Two and Phase Three in clinical trials, as well as a discussion on the prospects for this exciting new drug.
According the press release, recruitment for this phase is complete and topline data from all patients in the trial is expected in the fourth quarter of 2020. Additionally, the company reports paltusotine was well tolerated, and there were no discontinuations due to drug-related adverse events.
The release, which you can read here, provides a detailed review of the results.
I addition you can hear Dr. Scott Struthers, CEO and other Crinetics scientist, business leaders and patient advocates in this PWN podcasts series “The journey to a new drug “ available in the podcast section of Pituitary World News. Click here to listen to more podcasts in the series.
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
© 2020, Pituitary World News. All rights reserved.